文献速递肿瘤 PET/CT核素与放射性配体治疗

使用[68Ga]Ga-HER2亲和体PET/CT无创评估尿路上皮癌患者HER2表达的初步临床发现

Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-02-14

本研究从一项前瞻性母研究(NCT05535621)中回顾性纳入25例尿路上皮癌患者,序贯进行[68Ga]Ga-HER2亲和体PET/CT与[18F]FDG PET/CT,并以免疫组化评估HER2状态。结果显示HER2阳性原发肿瘤的[68Ga]Ga-HER2亲和体PET/CT SUVmax高于HER2阴性肿瘤,且SUVmax与HER2表达水平呈正相关(R=0.727,p=0.001),FDG SUVmax则与HER2表达无相关性。

要点

  • HER2阳性(IHC 2+、3+)原发肿瘤SUVmax高于HER2阴性(IHC 0、1+)(p=0.042)。
  • HER2表达组(IHC 1+、2+、3+)SUVmax高于HER2-zero组(IHC 0)(p=0.001)。
  • HER2 PET SUVmax与HER2表达水平正相关(R=0.727,p=0.001)。

核心结论

  • [68Ga]Ga-HER2亲和体PET/CT是评估尿路上皮癌患者HER2表达的有价值的无创方法。

研究设计与样本

  • 从一项前瞻性母研究(NCT05535621)中回顾性纳入25例尿路上皮癌患者,序贯进行[68Ga]Ga-HER2亲和体和[18F]FDG PET/CT。
  • HER2状态通过免疫组化病理评估,评分为0、1+、2+、3+。
  • PET/CT病灶摄取以最大标准化摄取值(SUVmax)定量。

主要发现

  • 25例患者平均年龄65.6岁±11.1(标准差),其中18例男性。
  • 原发肿瘤HER2状态:IHC 0共4例,IHC 1+共3例,IHC 2+共6例,IHC 3+共3例,7例未知但潜在HER2表达。
  • 1例输尿管造口复发患者HER2 IHC 1+,另1例经转移灶活检确认IHC 2+。
  • 在16例尿路上皮癌参与者中,HER2阳性原发肿瘤(IHC 2+和3+,n=9)的[68Ga]Ga-HER2亲和体PET/CT SUVmax高于HER2阴性肿瘤(IHC 0和1+,n=7)(中位SUVmax 7.07±0.69 vs. 4.48±1.14,p=0.042)。
  • HER2表达组(IHC 1+、2+、3+,n=12)与HER2-zero组(IHC 0,n=4)之间观察到类似差异(中位SUVmax 6.97±0.70 vs. 2.85±0.19,p=0.001)。

关键数值与推荐

  • HER2阳性定义为IHC 2+或3+,HER2阴性定义为IHC 0或1+。
  • HER2表达定义为IHC 1+、2+、3+,HER2-zero定义为IHC 0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recently, novel human epidermal growth factor receptor 2 antibody-drug conjugate therapies have shown remarkable efficacy in treating urothelial carcinoma, highlighting the growing need for comprehensive assessment of HER2 expression in tumors to identify patients who could benefit. However, non-invasive methods for assessing HER2 status in patients with urothelial carcinoma remain limited. This study aimed to preliminarily evaluate the clinical potential of [68Ga]Ga-HER2 affibody PET/CT for non-invasive assessment of HER2 expression in patients with urothelial carcinoma. MATERIALS AND METHODS: A cohort of 25 patients with urothelial carcinoma was retrospectively included from a prospective parent study (NCT05535621), and sequential PET/CT using [68Ga]Ga-HER2 affibody and [18 F] FDG was performed. HER2 status was assessed through pathological evaluation using immunohistochemistry, with scoring categories of 0, 1+, 2+, and 3+. Lesion uptake on PET/CT was quantified using the maximum standardized uptake value (SUVmax). Comparisons of SUVmax between primary tumor groups with different HER2 expression levels (HER2-positive IHC 2+, 3 + vs. HER2-negative IHC 0, 1+, and HER2-expression IHC 1+, 2+, 3 + vs. HER2-zero IHC 0) were conducted using nonparametric statistical tests. Additionally, the correlation between tumor SUVmax and HER2 expression status was analyzed, and the HER2 PET metastasis-positive rate at the patient level in metastatic urothelial carcinoma was determined. RESULTS: Twenty-five patients (mean age, 65.6 years ± 11.1 [SD]); 18 men) with urothelial carcinoma were enrolled. HER2 status in primary tumor was confirmed IHC 0 in four cases, IHC 1 + in three cases, IHC 2 + in six cases, IHC 3 + in three cases, and unknown in seven cases with potential HER2 expression. One patient with ureterostomy recurrence had HER2 IHC 1+, while another case was confirmed IHC 2 + through biopsy of metastatic lesion. In 16 participants with urothelial carcinoma, the SUVmax of HER2-positive primary tumors (IHC 2 + and 3+, n = 9) were higher than those of HER2-negative tumors (IHC 0 and 1+, n = 7) (median SUVmax, 7.07 ± 0.69 vs. 4.48 ± 1.14, p = 0.042) on [68Ga]Ga-HER2 affibody PET/CT. Additionally, a similar difference was observed between the HER2-expression group (IHC 1+, 2+, 3+, n = 12) and the HER2-zero group (IHC 0, n = 4) (median SUVmax, 6.97 ± 0.70 vs. 2.85 ± 0.19, p = 0.001). Primary tumors in 13 of the 16 patients were semi-quantitatively measurable on FDG PET/CT imaging, with no significant difference in FDG SUVmax between the HER2-positive and HER2-negative group (7 HER2-positive vs. 6 HER2-negative; median SUVmax: 19.56 ± 5.02 vs. 19.10 ± 3.13, p = 0.731). Spearman correlation analysis revealed a positive correlation between HER2 PET SUVmax and HER2 expression levels in primary urothelial carcinoma (R = 0.727, p = 0.001), whereas no correlation was found between FDG SUVmax and HER2 expression levels (p > 0.05). In 14 patients with metastatic urothelial carcinoma, HER2 affibody PET/CT identified HER2 PET-positive metastatic lesions with a 92.86% positivity rate (13/14). CONCLUSION: [68Ga]Ga-HER2 affibody PET/CT is a valuable non-invasive method for evaluating HER2 expression in patients with urothelial carcinoma. TRIAL REGISTRATION: NCT05535621. Registered 18 December 2021.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zou S, Liu Z, Zhou J, et al. Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings. Eur J Nucl Med Mol Imaging. 2025. PMID: 39951137. doi:10.1007/s00259-025-07142-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。